Therapy-related leukaemia cutis: a review.
Leukaemia cutis following chemotherapy for a malignancy is a multifactorial process that is dependent on the chemotherapeutic agent used, the dosing regimen, and the cumulative dose as well as potential contributing therapies such as radiation and possibly even hematopoietic support from granulocyte colony stimulating factor. In the right combination and in a patient with a conducive milieu of epigenetic factors, leukaemia can develop as a treatment complication. Leukaemia cutis is the specific infiltration of the skin by leukaemic cells and occurs most commonly when the underlying leukaemia is an acute myeloid leukaemia. Although it is well reviewed in the literature as a result of primary leukaemia, leukaemia cutis has only very rarely been reported in association with therapy-induced leukaemia. This article reviews the factors that contribute to therapy-related leukaemia and the development of leukaemia cutis.
Weinel
Sarah
S
Division of Dermatology, Department of Medicine, University of Louisville, Kentucky, USA. sweinel@hotmail.com
Malone
Janine
J
Jain
Dharamvir
D
Callen
Jeffrey P
JP
D000970:Antineoplastic Agents / Q000009:adverse effects*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000473:pathology*; D017254:Leukemic Infiltration / Q000175:diagnosis / Q000209:etiology*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011379:Prognosis; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects*; D012307:Risk Factors; D012867:Skin / Q000473:pathology*; D043823:Taxoids / Q000009:adverse effects; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors